Upload
raisantosh
View
254
Download
9
Tags:
Embed Size (px)
Citation preview
STUDY ABOUT THE STUDY ABOUT THE CADILA PHARMACEUTICAL CADILA PHARMACEUTICAL LIMITEDLIMITED
PREPARE BY-PREPARE BY-SANTOSH KUMARSANTOSH KUMARPGDMM-09/006PGDMM-09/006
About Cadila Pharmaceuticals Limited Cadila Pharmaceuticals Ltd., established in 1951, is a true Life Sciences company and over the years has emerged as the undisputed leader with largest range of therapeutic groups. The company covers the entire gamut of pharmaceuticals
HISTORYHISTORY
Largest privately held pharmaceutical companies in India Largest privately held pharmaceutical companies in India
Headquarter at AhmedabadHeadquarter at Ahmedabad
PI plants located at Ankleshwar, Vadodra and PatalgangaPI plants located at Ankleshwar, Vadodra and Patalganga
It has best Research and Development setups in IndiaIt has best Research and Development setups in India
It is manned by 350 scientists and engineers It is manned by 350 scientists and engineers
•They are from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, photochemistry and different disciplines of engineering
•It has a multicultural, multilingual and multinational work- force of more than 4000 employee including 200 people outside Indian 49countries of Africa,CIS,Japan,USA
•First Indian company to get IND approval by USFDAIt has four more INDs with USDFA
•One for pulmonary tuberculosis, rest for various type of cancer, e.g., Lung cancer, Prostrate cancer, Bladder cancer and Melanoma
MILESTONEMILESTONE
Best research and development set-ups in the Best research and development set-ups in the countrycountry
Host of BIOTECH product launchedHost of BIOTECH product launched Worlds first manufacture of immuvac-a unique Worlds first manufacture of immuvac-a unique
immunomodulatorimmunomodulator USFDA approvals for fluoxetine and Ethambutol USFDA approvals for fluoxetine and Ethambutol
manufacturing facilitiesmanufacturing facilities Asia’s only manufacture of Asia’s only manufacture of
‘SULFOLANE’(tetramethylene sulfone)‘SULFOLANE’(tetramethylene sulfone) Leadership in domestic marketing and distribution Leadership in domestic marketing and distribution
managementmanagement
INTERNATIONAL INTERNATIONAL BUSINESSBUSINESS A significant presence in the Americas, CIS country, A significant presence in the Americas, CIS country,
Africa, Central and South-east Asia, Oceanic Africa, Central and South-east Asia, Oceanic countries, Japan, Middle East and Europecountries, Japan, Middle East and Europe
It has offices in USA, Japan, Kenya, Nigeria, Russia, It has offices in USA, Japan, Kenya, Nigeria, Russia, Kazakhstan and ukrainKazakhstan and ukrain
International SBU plans to expand operations to International SBU plans to expand operations to more than 100 countries by 2010more than 100 countries by 2010
Focus is on building brands in the following Focus is on building brands in the following therapeutic segments:therapeutic segments:
Anti-infective, Gastrointestinal, Analgesic, Anti-infective, Gastrointestinal, Analgesic, Respiratory, Cardiovascular, Ophthalmology, Respiratory, Cardiovascular, Ophthalmology, Bio-tchnical products Bio-tchnical products
PRODUCT CAPACITYPRODUCT CAPACITY
MAIN PHARMA PRODOTION CAPACITYMAIN PHARMA PRODOTION CAPACITY Tablets: 3900 million/yearTablets: 3900 million/year Capsules: 150 million/yearCapsules: 150 million/year Liquid: 6000 million kilolitres/yearLiquid: 6000 million kilolitres/year Sterile vias: 84 million/yearSterile vias: 84 million/year Ampoules: 84 million/yearAmpoules: 84 million/year Granules: 15.6 tones/yearGranules: 15.6 tones/year
BETA LACTUM /CEPHALOSPORINBETA LACTUM /CEPHALOSPORIN
Dry sterile vials: 48 million/yearDry sterile vials: 48 million/year Dry syrup bottles: 27 million/yearDry syrup bottles: 27 million/year Capsules: 630 million/yearCapsules: 630 million/year Tablets: 510million/yearTablets: 510million/year
CHAMPION BRANDCHAMPION BRAND
ENVASENVAS ACILOCACILOC LMX, SYMBIOTIK,CLAXLMX, SYMBIOTIK,CLAX RABELOCRABELOC ACILOC RD, ZASOACILOC RD, ZASO MIXULIN,MONTELAST,NODONMIXULIN,MONTELAST,NODON First company in INDIA to introduceFirst company in INDIA to introduce RABEPRAZOLE and FOSINPRIL formulations RABEPRAZOLE and FOSINPRIL formulations
PRODUCTPRODUCT
It caters to over 50 therapeutic areasIt caters to over 50 therapeutic areas Cardiovascular, gastrointestinal, analgesics, Cardiovascular, gastrointestinal, analgesics,
haematinics, anti-invectives and antibiotics, haematinics, anti-invectives and antibiotics, respiratory agents, antidiabetics and immunologicalrespiratory agents, antidiabetics and immunological
Biotechonolgy products and digonontic kits, plants Biotechonolgy products and digonontic kits, plants tissue culturetissue culture
Rabies immunoglobin and diagnostic kits for Rabies immunoglobin and diagnostic kits for detection of HIV and HCVdetection of HIV and HCV
Companies also manufacturer tablet Companies also manufacturer tablet presses,capsule filling machine,pharma machinery presses,capsule filling machine,pharma machinery parts and hospital disposables like glovesparts and hospital disposables like gloves
MARKETING DIVISIONSMARKETING DIVISIONS
Magna-Practitioners, physicians, Magna-Practitioners, physicians, surgeons cardiologists, surgeons cardiologists, gastroenterologistsgastroenterologists
Maxima-Chest physians, Dentists, Maxima-Chest physians, Dentists, surgeons surgeons
Volta-cardiology, diabetology, Volta-cardiology, diabetology, nephrology, critical carenephrology, critical care
Oncocare –cadigran, caditrex,karplat,Oncocare –cadigran, caditrex,karplat,
FINANCIAL STATEMENT OF FINANCIAL STATEMENT OF CADILA HEALTHCARE OF CADILA HEALTHCARE OF 2006-072006-07
20062006 20072007 INCREASEINCREASE
TOTAL TOTAL INCOMEINCOME
Rs Rs 3754millio3754millionn
Rs4629millRs4629millionion
23.31%23.31%
NET SALENET SALE RS RS 3572millio3572millionn
Rs Rs 4429millio4429millionn
23.99%23.99%
NET NET PROFITPROFIT
Rs Rs 429million429million
Rs Rs 664million664million
34.96%34.96%